AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00846443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
Study NCT00846443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
Study NCT03681210 — intervention group
Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Study NCT01126138 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine
Description: Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
Study NCT01126138 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
Description: Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity
Study NCT01852201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Mechanical Thrombectomy
Description: Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
Study NCT02651155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone capsules
Study NCT02651155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lubiprostone placebo-matching capsules
Study NCT02644720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multifocal intraocular lens implantation
Description: In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
Study NCT02644720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal intraocular lens implantation
Description: In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
Study NCT02644720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery
Study NCT02644720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery
Study NCT02644720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multifocal intraocular lens (IOL) (Tecnis ZMB00)
Study NCT02644720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal intraocular lens (IOL) (Tecnis ZCB)
Study NCT01754961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 500,000 IU given orally on Day 1
Study NCT01754961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given orally on Day 1
Study NCT01713114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute measures of satiety and food intake at next meal
Study NCT04413591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based combination HIV prevention package
Description: The intervention compares the efficacy of a community-based comprehensive HIV/STI prevention package compared to standard of care (HIV testing, counseling, and referrals) among Female Sex Workers.
Study NCT00317499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept
Study NCT02133339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN-157
Study NCT02133339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03305055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Information included in arm descriptions
Study NCT03305055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Information included in arm descriptions
Study NCT03305055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Information included in arm descriptions
Study NCT04488640 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroid biopsy with ultrasound
Description: Patients with thyroid nodules who underwent ultrasound-guided core needle biopsy with a 20 gauge core needle biopsy apparatus were included in the study.
Study NCT04552704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
Description: Given IV
Study NCT04552704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IV
Study NCT03497533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TriCAR-T-CD19
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10\^6 CAR+ T cells/kg
Study NCT01903486 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apo-Prednisone Cordorol, Detasone - Prednisone
Description: Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
Study NCT02352883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02352883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo mastectomy
Study NCT02352883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo wide local excision
Study NCT02352883 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02352883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Undergo endocrine therapy
Study NCT02352883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02352883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02352883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT04809870 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
Study NCT02044627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C-ETC-1002]
Study NCT04215016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
Description: Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
Study NCT01712009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Study NCT01712009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Study NCT01713114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute measures of satiety and food intake at next meal
Study NCT01651416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Study NCT01651416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Study NCT01651416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin Piperaquine combination
Study NCT01651416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulphadoxine-pyrimethamine combination
Study NCT01872065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Study NCT01872065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03000426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Free gingival graft removal from palate for socket preservation
Study NCT03000426 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Free gingival graft
Description: Free gingival graft removal from palate for socket preservation
Study NCT03000426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
Study NCT03000426 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
Study NCT01940887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030
Study NCT01940887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab or aflibercept
Description: Patients are randomized to receive either bevacizumab or aflibercept
Study NCT01712009 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pegfilgrastim
Description: Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Study NCT01940887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab or aflibercept
Description: Patients are randomized to receive either bevacizumab or aflibercept
Study NCT01940887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E10030 sham injection
Description: Pressure on the eye with a syringe with no needle
Study NCT04109820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MitoQ
Description: Oral; 20mg once a day for 14 days
Study NCT01712009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
Study NCT04109820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Oral; 20mg once a day for 14 days
Study NCT01712009 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
Study NCT01270464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: 3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
Study NCT01270464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
Study NCT00511082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121
Description: Patients will receive OPB-31121 administered orally, once daily for 4 weeks.
Study NCT04688320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant nonimmunogenic staphylokinase
Description: 15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Study NCT04688320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
Study NCT03631615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)
Description: Patients will be given the perioperative treatment as below once recruited:~1. induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~2. within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~3. consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery.
Study NCT00832871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200 mg will be administered orally
Study NCT02429778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: Deep or diaphragmatic breathing is taught prior to relaxation.
Study NCT02429778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
Study NCT03468413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP1050 or Placebo
Description: Randomised, double-blinded, placebo-controlled
Study NCT02582450 — intervention group
Intervention type: OTHER
Intervention: Patients with haemophilia
Description: Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
Study NCT00819559 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PCRT
Description: Preoperative chemoradiotherapy
Study NCT00819559 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PCRT
Description: Preoperative chemoradiotherapy
Study NCT01883180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
Study NCT01859117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 x 10^6 cells
Description: 3 x 10\^6 cells administered on Study Days 1 and 8
Study NCT01859117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 x 10^6 cells
Description: 10 x 10\^6 cells administered on Study Days 1 and 8
Study NCT01712009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
Study NCT01859117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 x 10^6 cells
Description: 30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
Study NCT01859117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 x 10^6 cells
Description: 100 x 10\^6 cells administered on Study Days 1 and 8
Study NCT00801203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRCT
Description: Up to two administrations of the IRCT during a single cough testing session
Study NCT01941745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Half normal saline
Description: 2 ml/kg
Study NCT01941745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose rhCC10
Description: 1.5 mg/kg study drug (rhCC10)
Study NCT01941745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose rhCC10
Description: 5 mg/kg in 2 ml/kg
Study NCT05109884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA PET Scan
Description: \[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan
Study NCT05109884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
Study NCT01163643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% BOL-303242-X ophthalmic suspension
Description: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Study NCT01163643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% BOL-303242-X ophthalmic suspension
Description: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Study NCT02805660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - 50 mg
Description: Participants received mocetinostat three times weekly as an oral capsule.
Study NCT02805660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - 70 mg
Description: Participants received mocetinostat three times weekly as an oral capsule.
Study NCT02805660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - 90 mg
Description: Participants received mocetinostat three times weekly as an oral capsule.
Study NCT02805660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - Recommended Phase 2 Dose (70 mg)
Description: Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
Study NCT02805660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.
Study NCT00941863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 100 mg (50-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
Study NCT00941863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg (50-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
Study NCT00941863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg (50-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
Study NCT00941863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg (200-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
Study NCT00941863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg (Expansion)
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
Study NCT01337492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar
Description: 400 mg of Sorafenib
Study NCT04323033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PERS stent
Description: PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution.~The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1).
Study NCT02929693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: 250 mg oral once a day until progression or unacceptable toxicity develops
Study NCT02929693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gefitinib
Description: 250 mg oral once a day until progression or unacceptable toxicity develops
Study NCT02929693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi-yangyin-jiedu decoction
Description: Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.